{
  "title": "Targeted therapy in advanced -mutated colorectal cancer: systematic review and network meta-analysis\n-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic LandscapeClinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal CancerEffects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisBRAF mutation in metastatic colorectal cancerANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated \n-Mutant Metastatic Colorectal CancerMetastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upEuropean expert panel consensus on the clinical management of BRAF-mutant metastatic colorectal cancerAddition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trialsCetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation statusFOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE studyUpfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trialIndividual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal CancerFirst line therapy in stage IV BRAF mutated colorectal cancerPhase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal CancerPIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenibUnresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFREncorafenib Plus Cetuximab as a New Standard of Care for Previously Treated  V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON StudyRandomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)Encorafenib, Cetuximab, and mFOLFOX6 in -Mutated Colorectal CancerThe PRISMA extension for network meta-analysis: bringing clarity and guidance to the reporting of systematic reviews incorporating network meta-analysesPractical methods for incorporating summary time-to-event data into meta-analysis: updated guidancePractical methods for incorporating summary time-to-event data into meta-analysisRoB 2: a revised tool for assessing risk of bias in randomised trialsMethodological index for non-randomized studies (minors): development and validation of a new instrumentDevelopment, content validation, and reliability of the Assessment of Real-World Observational Studies (ArRoWS) critical appraisal toolGeneral Methods for Monitoring Convergence of Iterative SimulationsChecking consistency in mixed treatment comparison meta-analysisFOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 StudyBiweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX TrialFOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancerBevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trialThe influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial515MO Encorafenib + cetuximab (EC) + FOLFIRI for BRAF V600E-mutant metastatic colorectal cancer (mCRC): Updated results from the BREAKWATER safety lead-in (SLI)Cetuximab and vemurafenib plus FOLFIRI\u00a0(5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trialCombined PD-1, BRAF and MEK inhibition in BRAF colorectal cancer: a phase 2 trial624P Tolerability and safety of vemurafenib, cetuximab combined with camrelizumab for BRAF V600E-mutated /MSS metastatic colorectal cancerTunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I studyCobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With  Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyPhase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, <i>BRAF</i><sup>V600E</sup> metastatic colorectal cancerCombined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal CancerPilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patientsVemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 MutationsA Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) StudyUpdated results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with EC-na\u00efve metastatic BRAF V600E colorectal cancer (CRC) in the phase 1b/2 HERKULES-3 studyDabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trialSafety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAF-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access ProgramBinimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With  V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer StudyA Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal CancerPhase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E MutationA phase ib-II study of dabrafenib, trametinib, cetuximab plus irinotecan in patients with BRAF mutant metastatic colorectal cancer: Subgroup analysis and biomarker identificationEfficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trialBevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trialPhase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM)First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer GroupAddition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialMutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient OutcomeEfficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS studyPanitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancerFinal analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinomaFOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of \n-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) StudyLong-term Survival Update and Extended RAS Mutational Analysis of the CAIRO2 Trial: Addition of Cetuximab to CAPOX/Bevacizumab in Metastatic Colorectal CancerImpact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) studyPhase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII studyFOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and \u22653 circulating tumour cells: the randomised phase III VISN\u00da-1 trialFOLFIRINOX plus cetuximab (CET) or bevacizumab (BEV) in patients (pts) with initially unresectable colorectal liver metastases (CRLM) with BRAF mutated (mut) tumors: A subgroup analysis of the UNICANCER PRODIGE 14-ACCORD 21 (METHEP2) trialVIC Regimen (Vemurafenib/Irinotecan/Cetuximab) Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Unresectable or Metastatic Colorectal Cancer in Asian Patients: A Prospective Cohort StudyPhase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced <i>BRAF-</i>mutant colorectal cancer (<i>BRAFm</i> CRC)Combined BRAF, EGFR, and MEK Inhibition in Patients with \n-Mutant Colorectal CancerPanitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trialAnalysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal CancerEncorafenib and cetuximab versus irinotecan/cetuximab or FOLFIRI/cetuximab in Chinese patients with <i>BRAF</i> V600E mutant metastatic colorectal cancer: The NAUTICAL CRC study448P Efficacy of combinations of BRAF inhibitors and anti-EGFR antibodies in metastatic colorectal carcinoma (mCRC) patients with mBRAF in the real clinical practiceEncorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experienceEfficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter studyTreatment of metastatic colorectal cancer with BRAF V600E mutation: A multicenter real-world study in ChinaWJOG13219G: The Efficacy and Safety of FOLFOXIRI or Doublet plus Anti-VEGF Therapy in Previously Untreated BRAF Mutant Metastatic Colorectal Cancer: A Multi-Institutional Registry-Based Study (BRACELET Study)Real-World Outcomes of Patients With BRAF-Mutated Metastatic Colorectal Cancer Treated in the United StatesEncorafenib plus cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma: First effectiveness data of the European multi-centric, multi-national, non-interventional study\u2014BERING-CRCAdaptive mutability of colorectal cancers in response to targeted therapiesSEAMARK: randomized phase 2 study of pembrolizumab + encorafenib + cetuximab versus pembrolizumab alone for first-line treatment of BRAF V600E-mutant and microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC)Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer",
  "pmcid": "12628362",
  "features": {
    "sample_size": {
      "present": true,
      "count": 2,
      "unique_matches": [
        "sample size"
      ],
      "examples": [
        {
          "match": "sample size",
          "context": "gn), demographic information (sample size, data source), treatment (reg"
        },
        {
          "match": "sample size",
          "context": "ects of covariates, including sample size, study design, data source, m"
        }
      ]
    },
    "randomization": {
      "present": true,
      "count": 4,
      "unique_matches": [
        "randomise",
        "allocation"
      ],
      "examples": [
        {
          "match": "randomise",
          "context": "as tool version 2 (RoB 2) for randomised controlled trials,24 the Met"
        },
        {
          "match": "randomise",
          "context": "Methodological Index for Non-randomised Studies for single arm inter"
        },
        {
          "match": "randomise",
          "context": "nterventional studies and non-randomised controlled trials,25 the Ass"
        }
      ]
    },
    "blinding": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "blinded"
      ],
      "examples": [
        {
          "match": "blinded",
          "context": "V600E variants; we preferred blinded independent central review as"
        }
      ]
    },
    "allocation_concealment": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "interaction_subgroup": {
      "present": true,
      "count": 3,
      "unique_matches": [
        "heterogeneity"
      ],
      "examples": [
        {
          "match": "heterogeneity",
          "context": "s, indirectness, imprecision, heterogeneity, and incoherence. Two reviewe"
        },
        {
          "match": "Heterogeneity",
          "context": "and grade \u22653 adverse events. Heterogeneity across studies was evaluated"
        },
        {
          "match": "heterogeneity",
          "context": "odel was applied to allow for heterogeneity between studies in the treatm"
        }
      ]
    },
    "variable_definitions": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "outcome measure"
      ],
      "examples": [
        {
          "match": "outcome measure",
          "context": "tudies reporting quantifiable outcome measures. We restricted pairwise meta"
        }
      ]
    },
    "analysis_principles": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "intention-to-treat"
      ],
      "examples": [
        {
          "match": "intention-to-treat",
          "context": "ssessed data derived from the intention-to-treat population; we preferred trea"
        }
      ]
    },
    "itt_details": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "intention-to-treat population"
      ],
      "examples": [
        {
          "match": "intention-to-treat population",
          "context": "ssessed data derived from the intention-to-treat population; we preferred treatment relat"
        }
      ]
    },
    "software": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "error_measures": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "multiplicity_correction": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "normality_checks": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "p_values": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "secondary outcome"
      ],
      "examples": [
        {
          "match": "secondary outcome",
          "context": "was overall survival, and the secondary outcomes analysed were progression-fr"
        }
      ]
    },
    "confidence_intervals": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "comparative_stats": {
      "present": true,
      "count": 2,
      "unique_matches": [
        "\u03c72",
        "odds ratio"
      ],
      "examples": [
        {
          "match": "\u03c72",
          "context": "udies was evaluated using the \u03c72 statistic based on Cochran\u2019s"
        },
        {
          "match": "odds ratio",
          "context": "val and overall survival, and odds ratios with 95% CrIs were used to a"
        }
      ]
    },
    "non_parametric": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "advanced_modeling": {
      "present": true,
      "count": 6,
      "unique_matches": [
        "markov chain",
        "bayesian"
      ],
      "examples": [
        {
          "match": "bayesian",
          "context": "s using the meta package, and bayesian network meta-analysis using t"
        },
        {
          "match": "bayesian",
          "context": "a-analysis was performed in a bayesian framework using the Markov Ch"
        },
        {
          "match": "bayesian",
          "context": "igures S1 and S2). Within the bayesian framework, the network meta-a"
        }
      ]
    },
    "assumption_checks": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "survival_analysis": {
      "present": true,
      "count": 6,
      "unique_matches": [
        "overall survival",
        "hazard ratio"
      ],
      "examples": [
        {
          "match": "hazard ratio",
          "context": "reatment line), and outcomes (hazard ratios for overall survival and pro"
        },
        {
          "match": "Hazard ratio",
          "context": "wo or more controlled trials. Hazard ratios with 95% credible intervals"
        },
        {
          "match": "overall survival",
          "context": "tcomes of interest, including overall survival, progression-free survival, o"
        }
      ]
    },
    "regression_and_models": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "reporting_guidelines": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "prisma"
      ],
      "examples": [
        {
          "match": "PRISMA",
          "context": "ic Reviews and Meta-Analyses (PRISMA) extension statement for netw"
        }
      ]
    },
    "data_types": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "binary"
      ],
      "examples": [
        {
          "match": "binary",
          "context": "95% CrIs were used to assess binary endpoints, including objectiv"
        }
      ]
    },
    "dependency": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "clustering": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "missing_data": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "effect_size": {
      "present": true,
      "count": 3,
      "unique_matches": [
        "hazard ratio",
        "odds ratio"
      ],
      "examples": [
        {
          "match": "odds ratio",
          "context": "val and overall survival, and odds ratios with 95% CrIs were used to a"
        },
        {
          "match": "hazard ratio",
          "context": "reatment line), and outcomes (hazard ratios for overall survival and pro"
        },
        {
          "match": "Hazard ratio",
          "context": "wo or more controlled trials. Hazard ratios with 95% credible intervals"
        }
      ]
    },
    "post_hoc": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "baseline_reporting": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "advanced_modeling_extra": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "excluded"
      ],
      "examples": [
        {
          "match": "excluded",
          "context": "on of these outcomes.22 23 We excluded studies that included patient"
        }
      ]
    },
    "systematic_review_metrics": {
      "present": true,
      "count": 8,
      "unique_matches": [
        "deviance information criterion",
        "transitivity",
        "network fragmentation",
        "sucra",
        "credible interval",
        "rankogram",
        "surface under the cumulative ranking"
      ],
      "examples": [
        {
          "match": "SUCRA",
          "context": "the cumulative ranking curve (SUCRA) and rankogram: 0 denoted the"
        },
        {
          "match": "surface under the cumulative ranking",
          "context": "treatments by calculating the surface under the cumulative ranking curve (SUCRA) and rankogram:"
        },
        {
          "match": "rankogram",
          "context": "ive ranking curve (SUCRA) and rankogram: 0 denoted the worst treatmen"
        }
      ]
    },
    "diagnostic_metrics": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "model_details": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "domain_indicators": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    }
  },
  "feedback": {
    "overall_score": 2.5,
    "rigor_rating": "Low",
    "critical_gaps": [
      {
        "message": "Blinding present but allocation concealment details missing.",
        "evidence": "...V600E variants; we preferred blinded independent central review as..."
      },
      {
        "message": "P-values reported without effect sizes (e.g. Odds Ratio).",
        "evidence": "...was overall survival, and the secondary outcomes analysed were progression-fr..."
      },
      {
        "message": "Survival analysis used without verifying proportional hazards assumption.",
        "evidence": "...reatment line), and outcomes (hazard ratios for overall survival and pro..."
      },
      {
        "message": "P-values reported only as thresholds (e.g., P<0.05).",
        "evidence": "...was overall survival, and the secondary outcomes analysed were progression-fr..."
      },
      {
        "message": "Network fragmentation detected in systematic review.",
        "evidence": "...the cumulative ranking curve (SUCRA) and rankogram: 0 denoted the..."
      }
    ],
    "strengths": [
      {
        "message": "Blinding of participants/assessors documented.",
        "evidence": "...V600E variants; we preferred blinded independent central review as..."
      },
      {
        "message": "Exclusion criteria explicitly defined (transparency).",
        "evidence": "...on of these outcomes.22 23 We excluded studies that included patient..."
      },
      {
        "message": "Detailed reporting of network/meta-analysis metrics.",
        "evidence": "...the cumulative ranking curve (SUCRA) and rankogram: 0 denoted the..."
      },
      {
        "message": "Used Bayesian framework for evidence synthesis.",
        "evidence": "...the cumulative ranking curve (SUCRA) and rankogram: 0 denoted the..."
      }
    ],
    "actionable_recommendations": [
      {
        "item": "Allocation Concealment",
        "issue": "Method of concealment (e.g. opaque envelopes) not described.",
        "recommendation": "Specify how randomization sequence was concealed.",
        "source_text": "Blinding found but no 'concealment' terms."
      }
    ],
    "deterministic_audit": true
  }
}